$ADXN
Addex Therapeutics Ltd.
CIK:0001574232|SEC Filings
Consolidated Statements of Profit or Loss - CHF (SFr) |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
||||
| Consolidated Statements of Profit or Loss | ||||||
| Revenue from contract with customer | SFr 29,972 | SFr 404,102 | SFr 1,612,953 | [1] | ||
| Other income | 142,888 | 5,940 | 4,235 | [1] | ||
| Operating costs | ||||||
| Research and development | (671,651) | (854,305) | (1,186,692) | [1] | ||
| General and administration | (2,315,807) | (2,310,970) | (2,673,463) | [1] | ||
| Total operating costs | (2,987,458) | (3,165,275) | (3,860,155) | [1] | ||
| Operating loss | (2,814,598) | (2,755,233) | (2,242,967) | [1] | ||
| Finance income | 26,595 | 63,964 | [1] | |||
| Finance expense | (15,547) | (3,547) | (321,150) | [1] | ||
| Finance result | (15,547) | 23,048 | (257,186) | [1] | ||
| Share of net loss of investments accounted for using the equity method | (4,012,443) | (2,177,157) | ||||
| Net loss before tax from continuing operations | (6,842,588) | (4,909,342) | (2,500,153) | [1] | ||
| Income tax expense | 0 | 0 | 0 | [1] | ||
| Net loss from continuing operations | (6,842,588) | (4,909,342) | (2,500,153) | [1] | ||
| Net profit / (loss) from discontinued operations (attributable to equity holders of the Group) | 114,342 | 11,965,129 | (8,056,074) | [1] | ||
| Net profit / (loss) for the period | SFr (6,728,246) | SFr 7,055,787 | SFr (10,556,227) | [1] | ||
| Basic profit / (loss) per share for profit/(loss) attributable to the ordinary equity holders of the Company | SFr (0.06) | SFr 0.07 | SFr (0.14) | [1] | ||
| From continuing operations | (0.06) | (0.05) | (0.03) | [1] | ||
| From discontinued operations | 0.12 | (0.11) | [1] | |||
| Diluted profit / (loss) per share for profit/ (loss) attributable to the ordinary equity holders of the Company | (0.06) | 0.07 | (0.14) | |||
| From continuing operations | SFr (0.06) | (0.05) | (0.03) | |||
| From discontinued operations | SFr 0.12 | SFr (0.11) | ||||
| ||||||
Consolidated Balance Sheets - CHF (SFr) |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | SFr 1,638,612 | SFr 3,341,738 |
| Other financial assets | 5,130 | 6,496 |
| Trade and other receivables | 20,087 | 15,513 |
| Prepayments | 16,295 | 169,649 |
| Other short-term assets | 7,967 | |
| Total current assets | 1,680,124 | 3,541,363 |
| Non-current assets | ||
| Right-of-use assets | 33,530 | 41,578 |
| Equipment | 707 | 1,131 |
| Non-current financial assets | 7,086 | 7,089 |
| Investment accounted for using the equity method | 3,847,796 | 7,087,142 |
| Financial assets at fair value through other comprehensive income | 285,962 | |
| Derivative financial instrument | 509,067 | |
| Total non-current assets | 4,684,148 | 7,136,940 |
| Total assets | 6,364,272 | 10,678,303 |
| Current liabilities | ||
| Current lease liabilities | 7,680 | 7,306 |
| Payables and accruals | 1,191,284 | 794,787 |
| Total current liabilities | 1,198,964 | 802,093 |
| Non-current liabilities | ||
| Non-current lease liabilities | 27,008 | 34,688 |
| Retirement benefits obligations | 371,608 | 164,251 |
| Total non-current liabilities | 398,616 | 198,939 |
| Equity | ||
| Share capital | 2,186,545 | 1,843,545 |
| Share premium | 267,308,174 | 266,382,670 |
| Other equity | 64,620,223 | 64,620,223 |
| Treasury shares reserve | (1,014,980) | (869,708) |
| Other reserves | 31,757,431 | 31,062,996 |
| Accumulated deficit | (360,090,701) | (353,362,455) |
| Total equity | 4,766,692 | 9,677,271 |
| Total liabilities and equity | SFr 6,364,272 | SFr 10,678,303 |